Madrigal Pharmaceuticals, Inc. Share Price
Stocks
MDGL
US5588681057
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
10:32:53 18/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 530.83 USD | -0.67% |
|
-0.68% | -8.84% |
| Market Cap | 1.23TCr 1.08TCr 1.02TCr 923.15Cr 1.73TCr 1,18500Cr 1.74TCr 12TCr 4.7TCr 60TCr 4.64TCr 4.54TCr 1,93800Cr | P/E 2026 * |
-84.6x | P/E 2027 * | 84.9x |
|---|---|---|---|---|---|
| Enterprise Value | 1.18TCr 1.03TCr 973.41Cr 883.93Cr 1.66TCr 1,13400Cr 1.66TCr 12TCr 4.5TCr 58TCr 4.44TCr 4.34TCr 1,85600Cr | EV / Sales 2026 * |
7.75x | EV / Sales 2027 * | 5.32x |
| Free-Float |
94.17% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| MDGL | Delayed | |
CBOE
| MDGL | Real-time | |
|
Tradegate
| YDO1 | Real-time | |
|
Deutsche Boerse AG
| YDO1 | Delayed | |
|
Börse Stuttgart
| YDO1 | Delayed | |
|
Boerse Muenchen
| YDO1 | Real-time | |
|
Borsa Italiana
| 1MDGL | End-of-day quote | |
|
Xetra
| YDO1 | Delayed |
Last Transcript: Madrigal Pharmaceuticals, Inc.
| 1 day | -0.67% | ||
| 1 week | -0.68% | ||
| Current month | -1.69% | ||
| 1 month | +1.24% | ||
| 3 months | +4.97% | ||
| 6 months | +20.11% | ||
| Current year | -8.84% |
| 1 week | 513.36 |  | 541.34 |
| 1 month | 506.29 | | 552.08 |
| Current year | 416.21 | | 598.79 |
| 1 year | 393.6 | | 615 |
| 3 years | 119.76 | | 615 |
| 5 years | 52.33 | | 615 |
| 10 years | 9.87 | | 615 |
| Manager | Title | Age | Since |
|---|---|---|---|
William Sibold
CEO | Chief Executive Officer | 59 | 08/09/2023 |
Mardi Dier
DFI | Director of Finance/CFO | 62 | 11/03/2024 |
David Soergel
CTO | Chief Tech/Sci/R&D Officer | 58 | 21/04/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Rebecca Taub
BRD | Director/Board Member | 74 | 01/07/2016 |
Richard Levy
BRD | Director/Board Member | 68 | 11/08/2016 |
James Daly
BRD | Director/Board Member | 64 | 27/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 11/09/26 | Sell | Chief Executive Officer | -5,221 | 0.0226% | ||
| 17/08/26 | Sell | General Counsel | -664 | 0.0029% | ||
| 15/08/26 | Free | Director | 1,725 | 0.0075% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.67% | -0.68% | +20.45% | +224.54% | 1.23TCr | |
| -0.31% | +3.56% | +46.40% | +100.50% | 7.09TCr | |
| +0.39% | +2.06% | +40.91% | +78.49% | 6.23TCr | |
| -2.21% | -6.50% | -17.04% | +355.74% | 2.71TCr | |
| -2.68% | -0.69% | -0.26% | -11.90% | 2.48TCr | |
| +0.71% | +8.03% | +27.22% | -13.18% | 2.06TCr | |
| -1.26% | -10.61% | +170.72% | +290.48% | 1.55TCr | |
| -0.85% | +3.43% | +43.50% | +171.87% | 1.45TCr | |
| -0.90% | +0.14% | -8.61% | +870.99% | 1.41TCr | |
| -2.12% | -7.32% | +38.71% | +101.86% | 972.05Cr | |
| Average | -0.97% | +1.01% | +36.20% | +216.94% | 2.72TCr | |
| Weighted average by Cap. | -0.65% | +1.16% | +35.75% | +162.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 152.63Cr 133.09Cr 125.67Cr 114.12Cr 213.81Cr 15TCr 214.7Cr 1.51TCr 580.91Cr 7.45TCr 573.35Cr 560.62Cr 24TCr | 214.49Cr 187.03Cr 176.6Cr 160.37Cr 300.47Cr 21TCr 301.72Cr 2.12TCr 816.34Cr 10TCr 805.73Cr 787.84Cr 34TCr |
| Net income | -18Cr -16Cr -15Cr -14Cr -26Cr -1.76TCr -26Cr -181.34Cr -70Cr -896.99Cr -69Cr -68Cr -2.89TCr | 20Cr 17Cr 16Cr 15Cr 28Cr 1.92TCr 28Cr 197.25Cr 76Cr 975.67Cr 75Cr 73Cr 3.14TCr |
| Net Debt | -52Cr -46Cr -43Cr -39Cr -73Cr -5.03TCr -74Cr -517.32Cr -199.63Cr -2.56TCr -197.04Cr -192.66Cr -8.23TCr | -94Cr -82Cr -78Cr -71Cr -132.13Cr -9.05TCr -132.68Cr -930.28Cr -358.99Cr -4.6TCr -354.32Cr -346.45Cr -15TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/26/18 | $530.86 | -0.66% | 48,411 |
| 17/26/17 | $534.40 | +1.00% | 1,53,313 |
| 16/26/16 | $529.09 | +1.11% | 2,98,474 |
| 15/26/15 | $523.26 | -3.11% | 2,59,412 |
| 14/26/14 | $540.06 | +1.04% | 1,56,535 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MDGL Stock
Select your edition
All financial news and data tailored to specific country editions
